Regression-Based Proximal Reconciliation of Conflicting Trials with Unmeasured Effect Modifiers
存在未观测效应修饰变量时冲突试验的回归式近端协调AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要明确讨论未观测效应修饰、代理变量、试验间效应迁移与因果可协调性,直接对应因果推断。
存在未观测效应修饰变量时冲突试验的回归式近端协调AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
Randomized controlled trials with similar protocols may yield conflicting findings when the distribution of relevant effect modifiers differs across study populations. Yet no formal statistical framework exists for defining and assessing whether conflicting trials are reconcilable, despite the importance of this question for evidence synthesis and regulatory decision making. To address this gap, we develop a causal inference framework for evaluating conditional and marginal reconcilability on additive and multiplicative scales in the presence of unmeasured effect modifiers. Within this framework, we use proxy variables for hypothesized unmeasured effect modifiers to develop regression-based tests of conditional reconcilability under parametric structural models. To assess marginal reconcilability, we extend existing transportability methods and develop an equivalence testing framework. We also introduce a reconciliation proportion to quantify the degree of marginal reconciliation. We illustrate these methods using the conflicting Meis and PROLONG trials of 17-alpha-hydroxyprogesterone caproate for preventing recurrent preterm birth. The analyses provided limited evidence that unmeasured effect modifiers such as cervical length, as captured by the selected proxies, were sufficient to marginally reconcile the trials. These findings demonstrate how proximal reconciliation methods may help regulators, researchers, and clinicians evaluate whether differences in study populations explain conflicting trial findings.